Journal Mobile Options
Table of Contents
Vol. 159, No. 3, 2012
Issue release date: October 2012

How Can We Better Classify NSAID Hypersensitivity Reactions? – Validation from a Large Database

Caimmi S. · Caimmi D. · Bousquet P.-J. · Demoly P.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) is one of the most common drug hypersensitivities. Several clinical subtypes have been distinguished depending on symptomatology (respiratory, cutaneous, anaphylaxis), timing (immediate, delayed), underlying chronic disease (asthma, chronic urticaria) or putative mechanism of the reaction (allergic, nonallergic mediated). The aim of the present study was to better classify the many hypersensitivity reactions to NSAIDs. Methods: In the present retrospective study, during an 11-year study period, we collected data from all patients with a proven NSAID hypersensitivity. Reactions were classified according to clinical patterns, chronology, underlying diseases and the results of oral provocation tests into 5 and 7 groups in line with two published classifications, respectively. Results: Forty-nine and 88 out of 307 reactions (in 122 patients) could not be classified on the basis of the two previously published classifications. We created a new classification which could include all patient reactions. Conclusions: Our new classification is more suitable for clinical expression of NSAID hypersensitivity. It allows clinicians to identify patients at a high risk, based on the clinical history and clinical manifestations. Moreover, it is helpful for a better understanding and teaching of these reactions.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Conaghan PG: A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int 2011, E-pub ahead of print.
  2. Hamera-Słynarska M, Słynarski K: The undesirable side effects of non-steroidal anti-inflammatory drugs. Ortop Traumatol Rehabil 2001;3:126–128.
  3. Vervloet D, Durham S: Adverse reactions to drugs. BMJ 1998;316:1511–1514.
  4. Sánchez Borges M: NSAID hypersensitivity (respiratory, cutaneous, and generalized anaphylactic symptoms). Med Clin N Am 2010;94:853–864.
  5. Kim SH, Ye YM, Palikhe NS, Kim JE, Park HS: Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol 2010;10:280–290.
  6. Messaad D, Sahla H, Benahmed S, Godard P, Bousquet J, Demoly P: Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004;140:1001–1006.
  7. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, Bousquet P, Celik G, Demoly P, Gomes ER, Niżankowska-Mogilnicka E, Romano A, Sanchez-Borges M, Sanz M, Torres MJ, De Weck A, Szczeklik A, Brockow K: Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy 2011;66:818–829.
  8. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P, et al: Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003;58:854–863.
  9. Bousquet PJ, Demoly P, Romano A, et al: Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform: the Galenda project. Allergy 2009;64:194–203.

    External Resources

  10. Quiralte J, Blanco C, Delgado J, Ortega N, Alcantára M, Castillo R, Anguita JL, Sáenz de San Pedro B, Carrillo T: Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions. J Investig Allergol Clin Immunol 2007;17:182–188.
  11. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O’Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW: Second symposium on the definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391–397.
  12. Hinz B, Cheremina O, Brune K: Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008;22:383–390.
  13. Stevenson DD, Szczeklik A: Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006;118:773–786.
  14. Demoly P, Kropf R, Bircher A, Pichler WJ: Drug hypersensitivity: questionnaire. Allergy 1999;54:999–1003.
  15. Romano A, Bousqut-Rouanet L, Viola M, Gaeta F, Demoly P, Bousquet PJ: Benzylpenicillin skin testing is still important in diagnosing immediate hypersensitivity reactions to penicillins. Allergy 2009;64:249–253.
  16. Buhl T, Meynberg HC, Kaune KM, Hünecke P, Schön MP, Fuchs T: Long-term follow-up of patients with hypersensitivity to nonsteroidal anti-inflammatory drugs reveals shortcomings in compliance and care. J Allergy Clin Immunol 2011;127:284–285.

    External Resources

  17. Harrer A, Lang R, Grims R, Braitsch M, Hawranek T, Aberer W, Vogel L, Schmid W, Ferreira F, Himly M: Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites. PLoS One 2010;10:e13707.

    External Resources

  18. Stevenson DD, Sanchez-Borges M, Szczeklik A: Classification of allergic and pseudoallergic reactions to drug that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001;87:177–180.
  19. Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA: Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 2004;292:3017–3023.
  20. Quiralte J, Blanco C, Castillo R, Delgado J, Carrillo T: Intolerance to non-steroidal anti-inflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol 1996;98:678–685.
  21. Bluth MH, Beleza P, Hajee F, Jordao MJ, Figueiredo J, Almeida F, Smith-Norowitz T: IgE-mediated hypersensitivity after ibuprofen administration. Ann Clin Lab Sci 2007;37:362–365.
  22. Canto MG, Andreu I, Fernandez J, Blanca M: Selective immediate hypersensitivity reactions to NSAIDs. Curr Opin Allergy Clin Immunol 2009;9:293–297.
  23. Asero R: Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol 2003;111:1095–1098.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50